Kaken Pharmaceutical Co., Ltd.
KKPCFOTCHealthcare● Active
$26.78
+$0.78(+3.00%)
Market Cap$1.0B
P/E Ratio—
52W High$28.121
52W Low$22.3
Kaken Pharmaceutical Co., Ltd. (KKPCF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KKPCF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $77.35B | $94.03B | $72.04B | $72.98B | $76.03B |
| Cost of Revenue | $37.87B | $35.50B | $33.51B | $33.43B | $34.46B |
| Gross Profit | $39.49B | $58.53B | $38.54B | $39.56B | $41.58B |
| Gross Margin %(computed) | 51.05% | 62.24% | 53.49% | 54.20% | 54.68% |
| Operating Expenses | |||||
| R&D Expenses | $20.71B | $18.73B | $12.54B | $15.79B | $8.42B |
| G&A Expenses | $0.00B | $0.00B | $0.03B | $0.00B | $0.00B |
| Total Operating Expenses | $40.39B | $37.50B | $29.03B | $31.55B | $24.51B |
| Operating Income | ($0.90B) | $21.03B | $9.51B | $8.00B | $17.06B |
| Operating Margin %(computed) | -1.17% | 22.37% | 13.20% | 10.96% | 22.44% |
| Interest Income | $0.28B | $0.08B | $0.01B | $0.01B | $0.01B |
| Interest Expense | $0.05B | $0.03B | $0.02B | $0.02B | $0.02B |
| Income Before Tax | $2.33B | $19.43B | $9.80B | $6.82B | $13.88B |
| Income Tax Expense | $0.17B | $5.49B | $1.77B | $1.38B | $4.34B |
| Net Income | $2.16B | $13.95B | $8.03B | $5.44B | $9.55B |
| Net Margin %(computed) | 2.79% | 14.83% | 11.14% | 7.45% | 12.56% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $57.52 | $365.42 | $212.66 | $144.79 | $251.44 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B |
| EBITDA | $2.44B | $22.02B | $12.57B | $9.40B | $16.38B |
| EBITDA Margin %(computed) | 3.16% | 23.41% | 17.44% | 12.88% | 21.55% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · JPY · B
Explore more Kaken Pharmaceutical Co., Ltd. data
About Kaken Pharmaceutical Co., Ltd. (KKPCF) Income Statement
Kaken Pharmaceutical Co., Ltd. (KKPCF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, KKPCF reported revenue of $77.35B, gross profit of $39.49B (gross margin 51.05%), and net income of $2.16B — a net profit margin of 2.79%.
Frequently asked questions
KKPCF · 4 questionsKaken Pharmaceutical Co., Ltd. (KKPCF) reported revenue of $77.35B for 2026, down 17.7% year-over-year.
KKPCF revenueKKPCF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08